- TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
- TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
- TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
- TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
- TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
- TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
- TScan Therapeutics Announces Closing of Upsized Public Offering
- TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
- TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
More ▼
Key statistics
As of last trade TScan Therapeutics Inc (TCRX:NMQ) traded at 8.40, -13.36% below its 52-week high of 9.69, set on May 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.48 |
---|---|
High | 8.75 |
Low | 8.35 |
Bid | 8.36 |
Offer | 8.45 |
Previous close | 8.48 |
Average volume | 216.07k |
---|---|
Shares outstanding | 52.86m |
Free float | 48.17m |
P/E (TTM) | -- |
Market cap | 451.98m USD |
EPS (TTM) | -1.28 USD |
Data delayed at least 15 minutes, as of Jun 04 2024 16:05 BST.
More ▼